🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

If you want to explore more about OncoKB, please join us at #amp2023 #AMPath2023 booth #928

New OncoKB™ release people! AKT1 (& PIK3CA & PTEN onc mut) = Level 1 w/ pan-AKT inh capivasertib + fulvestrant U.S. FDA apprval for pts w/ breast cancer 🤔drug showed activity in overall ER+/HER2- popn +Reprotrectinib apprvd in ROS1+ NSCLC w/ activity against solvt front resist

New release my OncoKB™ people! Major updates: Removal of FGFR2-fusion+ #bladdercancer as L1 based on U.S. FDA amendmt to erdafitinib label +MDM2 amplification➡️L3A in intimal-& lipo-sarcomas based on compelling clinical activity of MDM2-p53 antag milademetan&brigimadlin resp

New OncoKB data release v4.15: KRAS G12C Level 2 in amp cancer with sotorasib/adagrasib. Addition of new EGFR R2 resist. mts to osimertinib and Level 3A sensit. mts to afatinib. Removal of FGFR1 amp in LUSC based on limited response to FGFRi... and more, including 4 new genes!

Please come see Moriah Heller Nissan, PhD present our OncoKB poster (Section 36, #3544) at #AACR24, with a detailed overview of OncoKB content, our 2023 updates in precision oncology features and our future plans! 📅 Monday, April 8 2024, 1:30 PM - 5:00 PM

New OncoKB data release v4.16: Release of CDx page incl biomarker, cancer type, drug & specimen type. BRAF fusions & V600 mts L1 in LGG. ERBB2 amp L2 in salivary gland cancer & L3A in solid tumors, the latter following FDA-approval of T-DXd for HER2+ (IHC3+) tumors + 7 new genes

Join us May 31-June 4 at the ASCO 2024 Annual meeting in Chicago at Booth # 37106 to meet our team, explore our latest developments and learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB licensing and content!

New OncoKB data release v4.17: POLE/D1 exo dom mts and MSI-H L2 in CRC and SBC w/ pembro, nivo, ipi+nivo & dostar. MTAP del L3A in solid tumors w/ AMG193 & MRTX1719. ALK G1202R & L1196M L2 in NSCLC w/ lorl. Mobocertinib removal from L1 EGFR exon 20 in-frame ins in NSCLC & more!

New OncoKB data release v4.18: KRAS G12C promoted to L1 in CRC w/ adagrasib + cetuximab. Osimertinib + chemo added as L1 in EGFR L858R & ex19del in NSCLC. Repotrectinib promoted to L1 in NTRK fusions in solid tumors. 5 new genes. And much more!

New OncoKB data release v4.20 IDH1 R132 & IDH2 R172 L1 in astrocytoma & oligodendroglioma w/ Vorasidenib. Inavolisib L3A in PIK3CA onc mts in breast cancer. Removal of H3B-8800. CCNE1 amp, FBXW7 & PPP2R1A mts L3A in endo and ovarian cancer w/ Lunresertib+Camonsertib. And more!

ALK F1174L/C, F1245Y/V & R1275Q/L L3A in neuroblastoma. MET H1094Y & F1200I L3A in NSCLC. MET N1100S, V1092I, H1106D, R1170Q & M1250T L4 in NSCLC. Promotion of Amivantamab + Lazertinib from L3A to L1 in EGFR L858R and ex19 inframe dels in NSCLC. 8 new genes. And more!

Join OncoKB Nov 19-23 at AMP 2024 in Vancouver! Stop by Booth 1421 to meet Hongxin Zhang and Ritika Kundra, explore our latest developments & learn how you can use OncoKB in your research or clinical practice. We are here to answer any questions regarding OncoKB! #AMPath24

New OncoKB data release v4.22: ROS1 G2032R & L2086F L3A and LR2 in NSCLC. SMARCA4 onc mts L3A in NSCLC and esophageal adenocarcinoma. Amivantamab+Chemo added to EGFR ex19 inframe-del & L858R L1 in NSCLC. Inavolisib+Palb+Fulv added to PIK3CA onc mts L1 in breast cancer. And more!